tbuckley/cabot-search huggingface dataset:
Impact of mammographic screening in staging, treatment and prognosis of breast cancer: Early assessment
Authors: A. Lluch, I. Chirivella, A. Insa, F. Martinez-Ruiz, A. Santaballa, C. Herranz, J. Ibañez, J. Miranda, C. Pons, D. Sala
Journal: Journal of Clinical Oncology (2006)

10537 Background: The use of breast cancer mammographic screening (MS) leads to early detection and has been shown to reduce the mortality rate and to increase the proportion of breast-conserving surgery. The aim of this study is to analyze the impact of mammography in the staging, treatment and prognosis of breast carcinoma. Methods: In 1993, a population-based mammographic screening among women aged from 45 to 70 years was introduced in the community of Valencia. We examined the effects of this MS program by the comparison of two populations. The first one included all the women with screen-detected invasive breast carcinoma between 1993 and 2002 in the community of Valencia. The second one was comprised of all the women with invasive breast carcinoma, diagnosed in the same period, aged 45–70, not attending the MS and treated at H. Clinico of Valencia. Results: Between January, 1993 and December, 2002, 2313 new invasive breast cancer patients were detected by the MS program in the community of Valencia, and 1349 women aged 45–70, not attending de MS were diagnosed with invasive breast carcinoma in H.Clinico of Valencia. The median follow-up period was 45.5 months for the screen-detected breast cancer and 51.9 months for not screen-detected patients. The screen-detected tumors had smaller pathological size (pT1 tumors 70.2% vs 40.5%, p &lt; 0.0001), were more likely to have pathologically confirmed negative nodal status (66.4% vs 52.2%, p &lt; 0.0001) and stage I disease (55.3% vs 26.1%, p &lt; 0.0001). Breast-conserving surgery was performed in 50.4% of patients with screen-detected tumors and in 31.9% of women who had not undergone MS (p &lt; 0.0001). The 5-year estimated survival was 95.5% (SE 0.57) for women with screen-detected breast cancer and 85.5% (SE 1.17) for those with not screen-detected tumors (p &lt; 0.0001). Conclusions: Our data demonstrate a better prognosis in terms of 5-year survival in screen-detected breast cancer patients that may explain why breast carcinoma mortality rates have decreased in recent decades. These patients have also been found to have smaller tumors, a more favorable tumor stage and a higher proportion of breast-conserving surgery. No significant financial relationships to disclose.
AN EXPLORATORY ANALYSIS OF THE PROGNOSTIC VALUE OF NEW ONSET BUNDLE BRANCH BLOCK IN STEMI
Authors: Adarsh Vangala, Paul Andre, Daniel Mills, Mark Sheldon, Stacy Clegg, Alex Schevchuck, Jerome Yatskowitz, Mark E. Garcia, Pamela Hsu, Veena Raizada
Journal: Journal of the American College of Cardiology (2020)
SURGICAL AND TRANSCATHETER MITRAL VALVE REPLACEMENT IN MITRAL ANNULAR CALCIFICATION- A SYSTEMATIC REVIEW
Authors: Sophia Alexis, Aaqib Malik, Isaac George, Ahmed El-Eshmawi, Susheel K. Kodali, Rebecca T. Hahn, Omar K. Khalique, Syed Zaid, Mayra Guerrero, Vinayak Bapat, Martin Leon, David Adams, Gilbert Tang
Journal: Journal of the American College of Cardiology (2020)
FUNCTIONAL MITRAL STENOSIS SEEN AFTER TRANS-JUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT IN A PATIENT WITH PRIOR HISTORY OF MITRAL VALVE REPAIR WITH ANNULOPLASTY RING
Authors: Stephanie Hsiao, Monika Young, Stacy Tsai, Rupsa Yee, Peter Hui
Journal: Journal of the American College of Cardiology (2020)
CLINICAL AND ECHOCARDIOGRAPHIC PREDICTORS OF AORTIC STENOSIS DISEASE PROGRESSION AND CLINICAL OUTCOMES IN PATIENTS WITH MODERATE AORTIC STENOSIS
Authors: Hemal Gada, Amit Vora, Basel Ramlawi, Daniel O'Hair, Miguel Sotelo, Chris Rogers, Loren Wagner, Logan Brigman, Navjot Kohli
Journal: Journal of the American College of Cardiology (2020)
Effect of immunization with the ii-key modified HER2/neu(776-790) (AE37) peptide vaccine on pre-existent immunity to PSA in HLA-A24+ prostate cancer patients: Association with increased AE37-specific immunologic responses.
Authors: Sonia A. Perez, Eleftheria Anastasopoulou, Efi Pappou, Nikolaos Fragkiskos Pistamaltzian, Eric von Hofe, Michael Papamichail, Constantin N. Baxevanis
Journal: Journal of Clinical Oncology (2012)

e15125 Background: In solid tumors such as prostate cancer, novel biomarkers are needed for assessing immunological responses and clinical efficacy. By using dextramers specific for PSA we have retrospectively analyzed CD8+ T cell frequencies in patients with HER-2/neu+ prostate cancer who had received the AE37 vaccine in a phase I study (Perez SA et al Clin. Cancer Res. 2010, 16:3495). AE37 binds to numerous MHC alleles (Perez SA et al Clin. Cancer Res. 2010, 16:3495) (Salazar LG, Clin Cancer Res. 2003, 9:5559) encouraging its use as a therapeutic vaccine for general HER-2/neu+ cancer patients. Methods: CD8+ Dextramer+ T cells were measured, retrospectively, in the blood (which was stored in N 2 liquid) of HLA-A24+ (n= 12) and HLA-A2+ (n=12) patients. Blood lymphocytes collected before, during and 6-months post vaccination were all analyzed with the same method involving direct labeling with HLA A24/PSA(153-161)-FITC and PerCP-conjugated anti-CD8 monoclonal antibody. Results: 8 of 12 HLA-A24+ patients had preexistent immunity to PSA as evidenced by the increased percentages of CD8+ HLA-A24/PSA(153-161)+ T cells in pre-vaccination samples. All of these patients had shown increased in vitro (IFNγ-based ELISPOT assay) and in vivo (DTH) immunological responses to the AE37 vaccine in the phase I study (Perez SA et al Clin. Cancer Res. 2010, 16:3495). Importantly, this preexistent immunity was significantly boosted in 5 patients during vaccinations with AE37, was slightly increased in 2 others, whereas in one patient no changes were observed during vaccinations. Conclusions: These results suggest that HLA-A24 expression along with preexistent immunity to PSA(153-164) may represent biomarkers based on which HER-2/neu+ patients can be selected most likely to benefit from vaccination with AE37. A phase II trial is warranted for validating these results. Given the promiscuity of AE37, it would be intriguing to examine if preexistent immunity to other prostate antigens restricted by various MHC alleles exist and to demonstrate an increase in preexistent immunity in association with a positive immunologic response to vaccination with AE37.
THE HOLY GRAIL OF IDENTIFYING PATIENTS NEEDING PERMANENT PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION WITH 100% ACCURACY
Authors: Jessica Roback, Tanvir Bajwa, Daniel O'Hair, Steven Port, Jayant Khitha, A. Jamil Tajik, Tonga Nfor, M. Fuad Jan, Suhail Allaqaband, Khawaja Afzal Ammar
Journal: Journal of the American College of Cardiology (2020)
EXTRA CARDIAC COMPRESSION OF RIGHT HEART BY HEPATIC CYSTS PRESENTING AS RIGHT HEART FAILURE: AN UNCOMMON CARDIAC COMPLICATION
Authors: Dakshin Gangadharamurthy, Sophia Thang, Khurram Nasir, Saurabh Malhotra, Alison Spangler, Thomas Flautt, Likhitesh Jaikumar, Paul Volansky, Mehul Patel, Madhab Ray, Theodore Richards, Jennifer Lindsey, Linnea Lebaron, Mandar Jagtap, Nanni Pidikiti, John W. Prather
Journal: Journal of the American College of Cardiology (2020)
CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study
Authors: Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, Kumar Alagapan
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study" published on 20 Mar 2020 by National Comprehensive Cancer Network.
IMPACT OFSYNTAX SCORE ON 10-YEAR CLINICAL OUTCOMES AFTER MYOCARDIAL REVASCULARIZATION FOR LEFT MAIN CORONARY ARTERY DISEASE
Authors: Duk-Woo Park, Yong-Hoon Yoon, Jung-Min Ahn, Do-Yoon Kang, Hanbit Park, Sang-Cheol Cho, Pil Hyung Lee, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2020)
INTRACAVITARY GRADIENTS IN MICE WITH EARLY REGIONAL REMODELING AT THE COMPENSATORY HYPERACTIVE STAGE PRIOR TO LV TISSUE DYSFUNCTION
Authors: Fatih Yalcin, Nagehan Kucukler, Oscar Cingolani, Blaid Mbiyangandu, Lars Lindholm Sorensen, Aurelio Carvalho Pinheiro, M. Roselle Abraham, Theodore P. Abraham
Journal: Journal of the American College of Cardiology (2020)
Biologicals in atopic disease in pregnancy: An EAACI position paper
Authors: Birgit Pfaller, Juan José Yepes‐Nuñez, Ioana Agache, Cezmi A. Akdis, Mohammad Alsalamah, Sevim Bavbek, Apostolos Bossios, Onur Boyman, Adam Chaker, Susan Chan, Alexia Chatzipetrou, George du Toit, Marek Jutel, Paula Kauppi, Antonios Kolios, Carmen Li, Andrea Matucci, Alanna Marson, Sarah Bendien, Oscar Palomares, Barbara Rogala, Zsolt Szepfalusi, Eva Untersmayr, Alessandra Vultaggio, Thomas Eiwegger
Journal: Allergy (2020)

Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scarce and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, preconception counseling and healthcare provider education are crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy.
UNDERSTANDING THE PATIENT PREFERENCE FOR CATHETER-BASED HYPERTENSION THERAPY: A PILOT STUDY FOR PHYSICIAN AWARENESS OF PATIENTS’ BEHAVIOR IN TAIWAN
Authors: Shu-I Lin, Sarah Hsiao-Wei Li, Wei-Ren Lan, Feng-Ching Liao, Cheng Ting Tsai, Ying-Hsiang Lee
Journal: Journal of the American College of Cardiology (2020)
Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA
Authors: Pat Gulhati, Jun Yin, Levi Pederson, Hans-Joachim Schmoll, Paulo Hoff, Jean-Yves Douillard, J Randolph Hecht, Christophe Tournigand, Niall Tebbut, Benoist Chibaudel, Aimery De Gramont, Qian Shi, Michael James Overman
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background Carcinoembryonic antigen (CEA) levels are used in conjunction with imaging to monitor response to systemic therapy in metastatic colorectal cancer (mCRC). We sought to identify a threshold for CEA change from baseline to predict progressive disease (PD) in mCRC patients receiving first-line therapy. Methods Patients from trials collected in the ARCAD database were included if baseline CEA was at least 10 ng/mL and repeat CEA was available within 14 days of first restaging scan. Optimal cutoffs for CEA change were identified by receiver operating characteristic analysis. Prediction performance of cutoffs was evaluated by sensitivity, specificity, and negative predictive value. Analyses were conducted by treatment class: chemotherapy alone, chemotherapy with anti-VEGF antibody, and chemotherapy with anti-EGFR antibody. Results A total of 2643 mCRC patients treated with systemic therapy were included. Median percent change of CEA from baseline to first restaging for patients with complete response, partial response, or stable disease (non-PD) and PD was −53.1% and +23.6% for chemotherapy alone (n = 957) and −71.7% and −45.3% for chemotherapy with anti-VEGF antibody (n = 1355). The optimal area under the curve cutoff for differentiating PD from non-PD on first restaging was −7.5% for chemotherapy alone and −62.0% for chemotherapy with anti-VEGF antibody; chemotherapy alone, adjusted odds ratio = 6.51 (95% CI = 3.31 to 12.83, P &amp;lt; .001), chemotherapy with anti-VEGF antibody, adjusted odds ratio = 3.45 (95% CI = 1.93 to 6.18, P &amp;lt; .001). A 99% negative predictive value clinical cutoff for prediction of non-PD would avoid CT scan at first restaging in 21.0% of chemotherapy alone and 16.2% of chemotherapy with anti-VEGF antibody–treated patients. Among patients with stable disease on first restaging, those with decreased CEA from baseline had statistically significantly improved progression-free and overall survival. Conclusions Change in CEA from baseline to first restaging can accurately predict non-progression and correlates with long-term outcomes in patients receiving systemic chemotherapy.
Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL)
Authors: I. Lang, J. Zaluski, C. R. Changchien, A. Makhson, T. Pinter, G. D’Haens, R. Lim, J. Nippgen, E. Van Cutsem
Journal: Journal of Clinical Oncology (2006)

3555 Background: Cetuximab is an IgG1 monoclonal antibody targeting the EGFR with proven activity in previously treated mCRC patients (pts). The modified two-weekly de Gramont regimen of irinotecan with infusional 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) is a standard for metastatic disease. This randomized trial investigates the effectiveness of cetuximab with this chemotherapy combination versus chemotherapy alone in (pts) with EGFR-expressing mCRC previously untreated for metastatic disease. Methods: This phase III trial compares cetuximab (400 mg/m 2 week 1 then 250 mg/m 2 weekly) added to FOLFIRI (irinotecan 180 mg/m 2 , FA 400 mg/m 2 , 5-FU bolus 400 mg/m 2 , 2400 mg/m 2 infusional 5-FU) (group A) vs. FOLFIRI alone (group B) in pts with EGFR-detectable tumors. 1080 pts are planned to detect a difference of ≥ 2 months in PFS with 80% power. The Data Safety Monitoring Board (DSMB) has performed an independent preplanned safety evaluation of 401 treated pts. Results: Pts (M/F 252/149, median age 62 years [range, 19–84], ECOG performance status [PS]: PS0, 57.1%: PS1, 38.4%: PS2, 4.5%) received at least 3 treatment cycles to date. Of the 401 pts, 83 (20.7%) pts completed/discontinued the trial. There were 11 deaths (2.7%) within 30 days of the last study treatment: 5 related to disease, 3 to chemotherapy, and 3 other (2 unknown, 1 intercurrent illness). Most common adverse events of the pooled safety data were skin reactions, diarrhea and nausea. Conclusions: After review of all relevant safety information by the DSMB, the trial continues. Recruitment was completed with 1220 patients in December 2005. [Table: see text] [Table: see text]
Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).
Authors: Ben Tran, Robert N Jorissen, Jayesh Desai, Fiona Day, Lara Rachel Lipton, Hui-Li Wong, Jeanne Tie, Ian Faragher, Ian Jones, Oliver Sieber, Peter Gibbs
Journal: Journal of Clinical Oncology (2013)

3598 Background: Aspirin has an established role in preventing CRC. Recent data suggests aspirin use may also benefit a subset of pts diagnosed with CRC. In one series, the authors identified PIK3CA mutations as a potential predictive biomarker for aspirin use, reporting that PIK3CA mutant CRC pts receiving aspirin had superior cancer specific survival (CSS) compared to those not receiving aspirin (HR 0.18, p&lt;0.001), whereas in pts with wildtype PIK3CA, aspirin had no survival impact. Our study aims to confirm the survival benefit associated with aspirin use in pts with PIK3CA mutant CRC. Methods: A cohort of CRC pts with PIK3CA mutations (Sanger sequencing) was identified. Prospectively collected clinicopathological, treatment and outcome data was available. Aspirin use was confirmed by chart review. CSS and overall survival (OS) analyses were conducted using Cox proportional hazards in univariate and multivariate settings. Recurrence free survival (RFS) analyses were limited to early stage CRC pts (Stage A-C). Statistical differences in 5-year CSS (5YS) rates were calculated using Fisher’s exact test. Results: From a cohort of 1,019 CRC pts with known PIK3CA mutation status, 121 (12%) harbored PIK3CA mutations. Of these, 112 (92%) had aspirin usage data available: 27 (24%) pts used aspirin, 85 (76%) did not. In the aspirin group, there were 22 (81%) early stage and 5 (19%) metastatic CRC pts; in the no-aspirin group, there were 59 (69%) early stage and 26 (31%) metastatic CRC pts. In univariate analyses, aspirin use was not associated with superior CSS (HR 0.57, p=0.21), OS (HR 0.83, p=0.57), or RFS (HR 0.72, p=0.57). In multivariate analyses, aspirin use was not associated with improved OS (HR 1.07, p=0.86), CSS (HR 1.04, p=0.94) or RFS (HR 0.54, p=0.34). In 69 (62%) pts with mature follow-up, there was a trend towards superior 5YS for aspirin users (69% v 42%, p=0.09), but this may reflect imbalances in stage at diagnosis. Conclusions: Our study was unable to confirm the recently reported survival benefit associated with aspirin use in pts with PIK3CA mutant CRC. Given the small numbers of pts, a modest survival benefit associated with aspirin use cannot be excluded. Analyses in an expanded cohort of early stage pts are underway.
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
Authors: William S. Weintraub, Deepak Bhatt, Zugui Zhang, Cheng Zhang, Dolman Sarahfaye, William E. Boden, Philippe Gabriel Steg, Michael Miller, Eliot Brinton, Jordan King, Adam Bress, Terry Jacobson, Jean Claude Tardif, Christie M. Ballantyne, Paul Kolm
Journal: Journal of the American College of Cardiology (2020)
Recurrence and survival outcomes following adjuvant therapy for early-stage uterine serous carcinoma (USC).
Authors: David A. Iglesias, Laura L. Holman, Shannon Neville Westin, Bryan Fellman, Kathleen M. Schmeler, Pedro T Ramirez, Michael M. Frumovitz, Karen H. Lu, Pamela T. Soliman
Journal: Journal of Clinical Oncology (2013)

e16556 Background: The choice of adjuvant therapy for early-stage USC remains controversial. The objective of this study was to estimate the recurrence rates of patients with surgically resected early-stage USC stratified by observation alone or adjuvant therapy. Methods: A retrospective review of women with surgically-staged stage IA-II USC followed at M.D. Anderson Cancer Center between January 2000 and December 2011. Descriptive statistics were used to summarize the demographic and clinical characteristics of patients. We estimated the cumulative incidence of disease recurrence, overall survival (OS), and recurrence-free survival (RFS) as a function of adjuvant therapy received. Adjuvant therapy groups listed in the Table. Results: 80 patients included in study. 58 patients had stage IA, 14 had stage IB, and 8 had stage II disease. Mean age was 66.4 years. Median follow-up for all patients was 4.83 years (range: 0.02 – 18.16). Cumulative incidence of recurrence for the whole group was 0.18 (95% CI: 0.10 – 0.28) which was reached at 3.96 years and remained at this rate until rising to 0.23 (95% CI: 0.12 – 0.36) at 11.12 years. Adjuvant treatment was not significantly associated with decreased risk of recurrence (Table). RFS at 5 years for the whole population was 0.71 (95% CI: 0.59 – 0.80) and OS at 5 years was 0.76 (95% CI: 0.63 – 0.85). Adjuvant treatment was not significantly associated with RFS or OS. In a subset of stage IA patients, 4 of 27 patients in the observation or cuff alone group recurred compared with 1 of 16 patients in the chemotherapy +/- cuff group (HR 0.48, CI: 0.05 – 4.27, p=0.511). Conclusions: In this study, there were no observed differences between observation and adjuvant treatment modalities in recurrence rates or survival outcomes for patients with early-stage USC. The addition of adjuvant chemotherapy may reduce risk for recurrence in stage IA patients, but further study is needed. [Table: see text]
Diffuse Metastases in Bilateral Penile Corpus Cavernosum From Renal Cancer Diagnosed by 18F-FDG PET/CT
Authors: Qiong Zou, Ju Jiao, Min-hong Zou, Ting Yang, Yong Zhang
Journal: Clinical Nuclear Medicine (2020)

Abstract We report a rare case of a 60-year-old man with diffuse metastases in bilateral penile corpus cavernosum after radical nephrectomy for left renal carcinoma. 18 F-FDG PET/CT demonstrated diffuse hypermetabolic lesions in bilateral penile corpus cavernosum, hypermetabolic tumor recurrences in left renal operation region, and left pulmonary metastasis. Biopsy confirmed penile metastasis from renal clear cell carcinoma. Diffuse penile metastatic carcinoma from renal cancer is extremely rare and associated with poor prognosis. 18 F-FDG PET/CT is helpful for diagnosis of penis metastasis and accurate staging of primary cancer.
INCIDENCE AND OUTCOMES OF BRADYARRHYTHMIA REQUIRING PACEMAKER AFTER CARDIAC TRANSPLANTATION: UPDATED UNOS ANALYSIS 2010 TO 2018
Authors: Haider Al Taii, Halah Abdulameer, Yoel Vivas, Luis Mora, Ramez Morcos, Mark Freher, Priya Bansal, Hamza Lodhi, Adithya Mathews, Eric Lieberman, Houman Khalili
Journal: Journal of the American College of Cardiology (2020)
The Menopause Transition and Cognition
Authors: Gail A. Greendale, Arun S. Karlamangla, Pauline M. Maki
Journal: JAMA (2020)

This JAMA Insights article summarizes the subjective cognitive problems experienced by some women during perimenopause (menopausal transition) and provides guidance to physicians on how to effectively answer patients’ questions and recognize when these symptoms may require clinical intervention.
An Ultra-Sensitive Step-Function Opsin for Minimally Invasive Optogenetic Stimulation in Mice and Macaques
Authors: Xin Gong, Diego Mendoza-Halliday, Jonathan T. Ting, Tobias Kaiser, Xuyun Sun, André M. Bastos, Ralf D. Wimmer, Baolin Guo, Qian Chen, Yang Zhou, Maxwell Pruner, Carolyn W.-H. Wu, Demian Park, Karl Deisseroth, Boaz Barak, Edward S. Boyden, Earl K. Miller, Michael M. Halassa, Zhanyan Fu, Guoqiang Bi, Robert Desimone, Guoping Feng
Journal: Neuron (2020)